country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-178045

Copy Link Print Information

MYC-IN-4

MYC-IN-4 is a MYC inhibitor. MYC-IN-4 impairs MYC/MAX protein-protein interaction (IC₅₀ = 3.06 μM). MYC-IN-4 inhibits MYC-aberrant PC-3 prostate cancer cells with an IC₅₀ of 0.440 μM. MYC-IN-4 demonstrates potent antitumor efficacy in FVB mice bearing Myc-CaP prostate tumor allografts. MYC-IN-4 can be used for the study of prostate cancer.

For research use only. We do not sell to patients.

CAS No.: 3109265-41-7
Formula: C₁₉H₁₀F₆N₂O₂
Molecular Weight:412.29

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (270 KB)

MYC-IN-4 Chemical Structure

CAS No.: 3109265-41-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vitro

MYC-IN-4 (Compound 15) exhibits potent antiproliferative activity against PC-3 cells (MYC-aberrant prostate cancer cells), with an IC₅₀ value of 0.440 μM^[1].
MYC-IN-4 (68 h) shows broad-spectrum antiproliferative activity against 14 other neoplastic cell lines, including MDA-MB-231, HCT-116, Myc-CaP, LN-CaP, NCI-H1581, A549, SK-N-BE, SK-OV-3, HepG-2, A-204, A-431, MG-63, LP-1, and MV4-11 cells, with IC₅₀ values ranging from 0.331 μM to 2.60 μM^[1].
MYC-IN-4 (10 μM, 1 h) significantly impairs MYC/MAX protein-protein interaction (PPI) in PC-3 cells via Co-IP assay^[1].
MYC-IN-4 (0.1-100 μM, 2 h) inhibits MYC/MAX PPI in a cell-free AlphaLISA assay, with an IC₅₀ value of 3.06 μM^[1].
MYC-IN-4 (10 μM, 1 h) reduces the thermal stability of endogenous MYC in PC-3 cells^[1].
MYC-IN-4 (1-10 μM, 24 h) induces concentration-dependent MYC degradation in PC-3 cells^[1].
MYC-IN-4 suppresses MYC transcriptional activity in HEK293T cells transfected with E-box luciferase reporter plasmid, with an IC₅₀ value of 0.739 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	T_1/2	AUC_0-t	V_ss	CL	F
Rat^[1]	10 mg/kg	i.p.	3.9 h	4330 ng·h/mL	12.8 L/kg	37.8 mL/min/kg	/
Rat^[1]	2 mg/kg	i.v.	1.39 h	1970 ng·h/mL	0.639 L/kg	17.2 mL/min/kg	44 %

In Vivo

MYC-IN-4 (Compound 15) (10-50 mg/kg, i.p., every other day, for 16 days) demonstrates potent antitumor efficacy in FVB mice bearing Myc-CaP prostate tumor allografts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Myc-CaP cells (1 × 10⁶ in 100 µL total volume) were subcutaneously implanted into the right flanks of 6-week-old male FVB mice to establish MYC-driven prostate tumor allograft models^[1]
Dosage:

10, 30, 50 mg/kg
Administration:

i.p., QOD for 16 days
Result:

Achieved tumor growth inhibition (TGI) rates of 57% and 70% at doses of 30 mg/kg and 50 mg/kg.
Showed no significant changes in body weight.
Reduced the Ki67 expression.
Combined with INCB086550 (HY-134884) increased the infiltration of CD8⁺ T cells and CD45⁺ leukocytes in the tumor microenvironment.

Chemical Information

CAS No. 3109265-41-7
Molecular Weight 412.29
Formula C₁₉H₁₀F₆N₂O₂
SMILES

OC1=C2C(OC(C3=CC=C(C=C3)C(F)(F)F)=C2)=CC=C1C4=CC(C(F)(F)F)=NN4
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Yang L, et al. Benzofuranyl-pyrazole as a Novel Scaffold for In Vitro and In Vivo Potent Anticancer Therapeutics That Directly Disrupt the 'Undruggable' MYC Oncogene and Potentiate Immune Checkpoint Blockage. J Med Chem. 2025 Sep 25;68(18):19184-19204. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote